Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc., a Delaware corporation, with a report date of August 5, 2026. The filing serves as a Regulation FD disclosure regarding a specific corporate event.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a non-financial corporate event rather than periodic financial results.
Material Changes and Events
On August 5, 2026, the company announced the issuance of a new United States Patent, No. 12,697,190. This event is disclosed under Item 7.01 (Regulation FD Disclosure) and is accompanied by a press release furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, or contingencies. The document explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the scope and commercial applicability of US Patent No. 12,697,190 by reviewing the attached press release (Exhibit 99.1).
- Confirm the patent's relevance to the company's core therapeutic pipeline.
- Note that this filing does not contain updated financial statements or liquidity data.